Ian R. Ferrier

Exponential Biotherapies, Inc. discovers and develops drugs. It provides small molecule drugs to treat an inflammatory disorders, such as acute kidney injury, septic shock, radiation sickness, and avian influenza infections. The company was founded on July 31, 1996 and is headquartered in New York, NY.

Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.